Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
08.06.2026 07:00
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effective immediately....
BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors
08.06.2026 07:00
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effective immediately....
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Mixed Recent Returns And Long Term Shareholder Gains
06.06.2026 08:06
Stock performance snapshot Vertex Pharmaceuticals (VRTX) is drawing investor attention after recent trading left the stock around US$446.83, with returns mixed across different periods and a longer term track record that stands in contrast to more recent moves. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been choppy, with a 1-day share price return of 1.15% and a 30-day share price return of 4.49%, while the 1-year total shareholder return has slipped 0.81% and the...
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
05.06.2026 16:00
BOSTON, June 05, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, present
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
05.06.2026 15:30
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should FDA’s IgA Nephropathy BLA Acceptance for Povetacicept Reshape Vertex Pharmaceuticals’ (VRTX) Investment Narrative?
02.06.2026 16:09
Vertex Pharmaceuticals recently reported that the FDA accepted its Biologics License Application for povetacicept in adults with immunoglobulin A nephropathy, with a PDUFA action date set for November 30, 2026, supported by Phase 3 data showing clinically meaningful reductions in proteinuria. This milestone marks a potential first commercial product in Vertex’s nephrology franchise, signaling progress in diversifying beyond its cystic fibrosis core. Next, we’ll explore how the FDA’s...
Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing
02.06.2026 16:02
Vertex Pharmaceuticals (NASDAQ:VRTX) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cash, while Wall Street prices it closer to a generic large-cap biotech than to the cash-flow compounder its financials describe. For a retirement-focused investor who has been burned chasing momentum, this is ... Got $5,000? 1 Cash-Flow King to Buy and Hold Forever That Wall Street Is Completely Mispricing
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
02.06.2026 15:09
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
31.05.2026 16:31
One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk profiles stack up for 2026.
These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth
28.05.2026 15:04
If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech ... These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout
28.05.2026 08:40
Vertex Pharmaceuticals (VRTX) combines strong fundamental growth with a promising technical setup, featuring a 7/10 setup rating and zero debt for a potential breakout opportunity.
Vertex’s Jounavx made history, but still left a void in the pain space
28.05.2026 08:34
The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness
21.05.2026 11:11
Vertex Pharmaceuticals (VRTX) stock has moved lower recently, with the price down about 2% over the past month and roughly 8% over the past 3 months, prompting closer attention from investors. See our latest analysis for Vertex Pharmaceuticals. Zooming out, Vertex’s recent share price weakness, including a 1-day share price return of down 0.89% and a 7-day share price return of down 4.99%, sits against a 5-year total shareholder return of 108.14%. This points to fading short term momentum...
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
16.05.2026 00:12
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
09.05.2026 06:07
Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
08.05.2026 13:00
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
08.05.2026 13:00
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
06.05.2026 12:45
Vertex Pharmaceuticals Incorporated beat Q1 2026 earnings, but CF growth is slowing and diversification faces hurdles. Click for this VRTX update.
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
06.05.2026 12:45
Vertex Pharmaceuticals Incorporated beat Q1 2026 earnings, but CF growth is slowing and diversification faces hurdles. Click for this VRTX update.
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $615
06.05.2026 11:43
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $607 to $615.